Multiple myeloma (MM) is a uniformly fatal disease characterized by a clonal proliferation of neoplastic plasma cells in the bone marrow and is the second most commol hematological malignancy.1 At present, a cure for multiple myeloma has not been achieved with chemotherapeutic regimen, and many patients die of drug-resistant disease. Thus, the development of new effective anticancer agents to treat both early and advanced MM seems to be an attractive perspective.